Abstract:OBJECTIVE: To explore changes in the plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in patients with left-to-right shunt congenital heart disease (CHD) before and in the early stage after interventional occlusion and to evaluate the clinical significance. METHODS: Among 97 patients with left-to-right shunt CHD undergoing interventional occlusion, 34 cases had a VSD (ventricular septal defect), 35 cases had an ASD (atrial septal defect), and 28 cases had PDA (patent ductus arteriosus). Another 20 normal adults formed the control group. An ELISA was used to determine the plasma ANP and BNP levels before and on the third day after the operation to evaluate their correlations with cardiac functions and the defect size. RESULTS: The plasma ANP and BNP levels of patients with left-to-right shunt CHD were increased compared with those of the normal control group (P < 0.01), and the plasma ANP and BNP levels were decreased on the third day after interventional occlusion compared with the preoperative levels (P < 0.05). The plasma ANP and BNP levels were correlated with the New York Heart Association (NYHA) grade, left ventricular ejection fraction and defect diameter (P < 0.05). CONCLUSION: Patients with left-to-right congenital heart disease exhibit activation of ANP and BNP, which can be alleviated in the early stage after intervention occlusion. Left-to-right shunt congenital heart disease is given priority over atrial septal defect (ASD), ventricular septal defect (VSD) and patent ductus arteriosus (PDA). Early traditional methods included repair or correction by open heart surgery under extracorporeal circulation (also known as cardiopulmonary bypass, CPB). However, interventional therapy has become a developing trend for the treatment of congenital heart disease since 1967, when Porstmann et al. [1]. reported the transcatheter closure of ASD for the first time. The application of the AMPLATZER occluder, which is a simple and feasible method, has improved the safety of the treatment and enabled the therapeutic effect to reach ideal levels. The natriuretic peptide (NP) family consists of the atrial natriuretic polypeptide (ANP), the brain natriuretic peptide, which is also known as the B type natriuretic peptide (BNP), the C type natriuretic peptide (CNP), the renal natriuretic peptide (RNP) and the D type natriuretic peptide (DNP). These family members are similar in structure, have strong natriuretic, diuretic and vasodilative effects and antagonize the activity of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nerve. Together, the natriuretic peptides sensitively and specifically reflect the ventricular function state. Although all types of congenital heart disease differ in anatomical structure, they all contain the common features of heart failure. This study detected changes in the serum ANP and BNP levels in patients with left-to-right shunt congenital heart disease before and on the third day after interventional occlusion to evaluate the early changes in left-to-right shunt congenital heart disease after interventional occlusion through neuroendocrine.

Significance of plasma BNP and ANP variations after transcatheter closure of ventricular septal defect

Quantitative Evaluation of Left and Right Ventricular Function by Serial Measuring Tei Index in Patients with Atrial Septal Defects Before and After Amplatzer Closure

Changes in Right Ventricular Volume and Plasma Atrial Natriuretic Peptide Level During Transcatheter Closure of Atrial Septal Defect

Changes of Plasma B-type Natriuretic Peptide after Percutanouse Balloon Mitral Valvuloplasty

Changes in Cardiac Size, Plasma Atrial Natriuretic Peptide and Endothelin Before and after Transcatheter Closure of Atrial Septal Defect

The Changes of Tei Index and Natriuretic Peptides after Transcatheter Closur of Patent Ductus Arteriosus

The Effect and Significance of Transcatheter Closure on Heart Rate Variability in Patients with Ventricular Septal Defect

Clinical effect of transcatheter closure on ventricular septal defect

Level Change of Plasma N-terminal Pro-Brain Natriuretic Peptide Before and after Interventional Therapy and the Relationship with Cardiac Performance in Children with Ventricular Septal Defect

Premature cardiovascular ultrasonographic variations after transcatheter closure in patients with patent ductus arteriosus

Immediate and mid-term changes of left ventricular systolic function after percutanous transcatheter closure of ventricular septal defect

Comparative Observation of Changes in Natriuretic Peptides Before and after Interventional Therapy for Congenital Heart Disease

Clinical evaluation of transcatheter closure on pseudoaneurysm of perimembranous ventricular septum in intermediate term

Application And Clinical Value Of Percutaneous Vsd Closure Guided By Echocardiography Alone

Plasma N-terminal pro-brain natriuretic peptide levels are positively correlated with degree of pulmonary arterial pressure in atrial septal defect patients

The Prevention and Treatment of Arrhythmia During the Transcatheter Closure of Ventricular Septal Defect

Atrial Natriuretic Peptide and Three-Dimensional Echocardiography after Transcatheter Closure of Atrial Septal Defect

Effect of perindopril on left heart remodeling after transcatheter closure of ventricular septal defects with domestic occluder

Clinical efficacy for transthoracic closure of congenital ventricular septal defect

Effects of Enalapril or Metoprolol on plasm brain natriuretice peptide in congenital heart disease combined with pulmonary artery hypertension after transcatheter closure

Acute Effect of Transcatheter Closure on Right Ventricular Function in Patients with Atrial Septal Defect Assessed by Tissue Doppler Imaging.